1. Home
  2. OMDA vs CGEM Comparison

OMDA vs CGEM Comparison

Compare OMDA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omada Health Inc.

OMDA

Omada Health Inc.

N/A

Current Price

$14.44

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$10.23

Market Cap

999.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OMDA
CGEM
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
999.4M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
OMDA
CGEM
Price
$14.44
$10.23
Analyst Decision
Buy
Strong Buy
Analyst Count
12
12
Target Price
$26.92
★ $34.70
AVG Volume (30 Days)
★ 1.2M
799.9K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 94.27
N/A
EPS
★ 0.14
N/A
Revenue
★ $260,210,000.00
N/A
Revenue This Year
$30.17
N/A
Revenue Next Year
$20.40
N/A
P/E Ratio
$104.93
★ N/A
Revenue Growth
★ 53.24
N/A
52 Week Low
$10.28
$8.23
52 Week High
$25.45
$23.19

Technical Indicators

Market Signals
Indicator
OMDA
CGEM
Relative Strength Index (RSI) 29.92 30.81
Support Level $14.01 N/A
Resistance Level $15.11 $16.31
Average True Range (ATR) 0.92 1.25
MACD -0.38 -0.28
Stochastic Oscillator 4.98 7.50

Price Performance

Historical Comparison
OMDA
CGEM

About OMDA Omada Health Inc.

Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: